X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (121) 121
index medicus (92) 92
female (83) 83
male (77) 77
middle aged (72) 72
oncology (72) 72
lung cancer (71) 71
aged (65) 65
lung neoplasms - genetics (61) 61
lung neoplasms - pathology (48) 48
adult (47) 47
hardware (43) 43
cancer (42) 42
lung neoplasms - drug therapy (42) 42
adenocarcinoma (38) 38
aged, 80 and over (36) 36
adenocarcinoma - genetics (34) 34
gefitinib (34) 34
chemotherapy (31) 31
computer architecture (30) 30
lung cancer, non-small cell (30) 30
mutation (30) 30
research (30) 30
carcinoma, non-small-cell lung - drug therapy (29) 29
smoking (28) 28
respiratory system (27) 27
digital signal processing (25) 25
video coding (25) 25
image coding (24) 24
lung neoplasms - mortality (23) 23
adenocarcinoma - pathology (22) 22
analysis (22) 22
carcinoma, non-small-cell lung - pathology (22) 22
motion estimation (22) 22
prognosis (22) 22
cell line, tumor (21) 21
metastasis (21) 21
mpeg 4 standard (21) 21
discrete wavelet transforms (20) 20
carcinoma, non-small-cell lung - genetics (19) 19
genetic aspects (19) 19
polymorphism, single nucleotide (19) 19
adenocarcinoma of lung (18) 18
antineoplastic agents - therapeutic use (18) 18
bandwidth (18) 18
health aspects (18) 18
receptor, epidermal growth factor - genetics (18) 18
transform coding (18) 18
apoptosis (17) 17
carcinoma, non-small-cell lung - mortality (17) 17
decoding (17) 17
design engineering (17) 17
disease-free survival (17) 17
genetic predisposition to disease (17) 17
adenocarcinoma - drug therapy (16) 16
animals (16) 16
block codes (16) 16
costs (16) 16
engineering, electrical & electronic (16) 16
lung neoplasms - metabolism (16) 16
non-small cell lung cancer (16) 16
survival (16) 16
treatment outcome (16) 16
calculating (15) 15
care and treatment (15) 15
case-control studies (15) 15
computing (15) 15
counting (15) 15
epidermal growth factor (15) 15
expression (15) 15
neoplasm staging (15) 15
physics (15) 15
risk (15) 15
risk factors (15) 15
throughput (15) 15
tumors (15) 15
electricity (14) 14
erbb receptors - genetics (14) 14
medical colleges (14) 14
medicine (14) 14
algorithm design and analysis (13) 13
algorithms (13) 13
cell biology (13) 13
electric communication technique (13) 13
encoding (13) 13
erlotinib (13) 13
genome-wide association study (13) 13
genotype (13) 13
growth-factor receptor (13) 13
interpolation (13) 13
mutations (13) 13
pictorial communication, e.g. television (13) 13
retrospective studies (13) 13
activation (12) 12
breast-cancer (12) 12
lung adenocarcinoma (12) 12
mice (12) 12
oncology, experimental (12) 12
quinazolines - therapeutic use (12) 12
research article (12) 12
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 05/2014, Volume 32, Issue 15_suppl, pp. e22040 - e22040
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2017, Volume 35, Issue 15_suppl, pp. e13103 - e13103
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2018, Volume 379, Issue 21, pp. 2027 - 2039
In a randomized trial involving patients with ALK -rearranged lung cancer, brigatinib was associated with longer progression-free survival and more activity... 
MEDICINE, GENERAL & INTERNAL | CERITINIB | EML4-ALK FUSION GENE | RESISTANCE | OPEN-LABEL | KINASE INHIBITOR | SINGLE-ARM | EGFR | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - chemistry | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Brain Neoplasms - secondary | Carcinoma, Non-Small-Cell Lung - secondary | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Organophosphorus Compounds - adverse effects | Crizotinib - therapeutic use | Lung Neoplasms - chemistry | Anaplastic Lymphoma Kinase - analysis | Kaplan-Meier Estimate | Organophosphorus Compounds - therapeutic use | Crizotinib - adverse effects | Pyrimidines - therapeutic use | Progression-Free Survival | Pyrimidines - adverse effects | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Anaplastic Lymphoma Kinase - antagonists & inhibitors | Crizotinib | Cancer patients | Safety and security measures | Development and progression | Dosage and administration | Comparative analysis | Lung cancer, Non-small cell | Drug therapy | Health aspects | Nuclear magnetic resonance--NMR | Medical imaging | Statistical analysis | Lung cancer | Non-small cell lung carcinoma | Metastasis | Radiation therapy | Lymphoma | Cancer therapies | Chemotherapy | Technical communication | Mutation | Protein-tyrosine kinase | Drug dosages | Pharmaceuticals
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 8, pp. 777 - 786
Summary Background The results of FASTACT, a randomised, placebo-controlled, phase 2 study, showed that intercalated chemotherapy and erlotinib significantly... 
Hematology, Oncology and Palliative Medicine | PHASE-III TRIAL | CARBOPLATIN-PACLITAXEL | 1ST-LINE TREATMENT | GEFITINIB | MULTICENTER | THERAPY | NSCLC | ONCOLOGY | ADENOCARCINOMA | OPEN-LABEL | EGFR | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Cisplatin - administration & dosage | Time Factors | DNA Mutational Analysis | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Genetic Predisposition to Disease | Lung Neoplasms - enzymology | Double-Blind Method | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Administration, Intravenous | Phenotype | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Asia | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Deoxycytidine - analogs & derivatives | Antimitotic agents | Medical colleges | Care and treatment | Chemotherapy | Clinical trials | Lung cancer, Non-small cell | Antineoplastic agents | Tumors | Cancer | Index Medicus
Journal Article
Nature Communications, ISSN 2041-1723, 03/2014, Volume 5, Issue 1, p. 3472
Journal Article
by Garassino, Marina Chiara and Cho, Byoung-Chul and Kim, Dong-Wan and Kim, Joo-Hang and Kim, Sang-We and Kim, Young-Chul and Mazières, Julien and Vansteenkiste, Johan and Lena, Hervé and Corral Jaime, Jesus and Gray, Jhanelle E and Powderly, John and Chouaid, Christos and Bidoli, Paolo and Wheatley-Price, Paul and Park, Keunchil and Soo, Ross A and Huang, Yifan and Wadsworth, Catherine and Dennis, Phillip A and Rizvi, Naiyer A and Paz-Ares Rodriguez, Luis and Novello, Silvia and Hiret, Sandrine and Schmid, Peter and Laack, Eckart and Califano, Raffaele and Maemondo, Makoto and Chaft, Jamie and Vicente Baz, David and Berghmans, Thierry and Surmont, Veerle and Reck, Martin and Han, Ji-Youn and Holgado Martin, Esther and Belda Iniesta, Cristobal and Oe, Yuichiro and Chella, Antonio and Chopra, Akhil and Robinet, Gilles and Soto Parra, Hector and Thomas, Michael and Cheema, Parneet and Katakami, Nobuyuki and Su, Wu-Chou and Wolf, Juergen and Lee, Jong-Seok and Saka, Hideo and Milella, Michele and Ramos Garcia, Inmaculada and Sibille, Anne and Yokoi, Takashi and Kang, Eun Joo and Atagi, Shinji and Spaeth-Schwalbe, Ernst and Nishio, Makoto and Imamura, Fumio and Gabrail, Nashat and Veillon, Remi and Derijcke, Sofie and Maeda, Tadashi and Zylla, Dylan and Kubiak, Kendra and Santoro, Armando and Uy, Ma. Noemi and Lucien Geater, Sarayut and Italiano, Antoine and Kowalski, Dariusz and Barlesi, Fabrice and Chen, Yuh-Min and Spigel, David and Chewaskulyong, Busyamas and Garcia Gomez, Ramon and Alvarez Alvarez, Rosa and Yang, Chih-Hsin and Hsia, Te-Chun and Denis, Fabrice and Sakai, Hiroshi and Vincent, Mark and Goto, Koichi and Bosch-Barrera, Joaquim and Weiss, Glen and Canon, Jean-Luc and Scholz, Christian and Aglietta, Massimo and Kemmotsu, Hirotsugu and Azuma, Koichi and Bradbury, Penelope and Feld, Ronald and Chachoua, Abraham and Jassem, Jacek and Juergens, Rosalyn and Palmero Sanchez, Ramon and Malcolm, Albert and Vrindavanam, Nandagopal and Kubota, Kaoru and Waller, Cornelius and Waterhouse, David and Coudert, Bruno and Mark, Zsuzsanna and ... and ATLANTIC Investigators
The Lancet Oncology, ISSN 1470-2045, 04/2018, Volume 19, Issue 4, pp. 521 - 536
Immune checkpoint inhibitors are a new standard of care for patients with advanced non-small-cell lung cancer (NSCLC) without tyrosine kinase or anaplastic... 
MULTICENTER | METAANALYSIS | NSCLC | ONCOLOGY | RANDOMIZED CONTROLLED-TRIAL | ATEZOLIZUMAB | IMMUNE CHECKPOINT | NIVOLUMAB | MEDI4736 | CLINICAL ACTIVITY | DOCETAXEL | Lung cancer, Non-small cell | Care and treatment
Journal Article
Cancer Cell, ISSN 1535-6108, 2008, Volume 13, Issue 1, pp. 48 - 57
Journal Article
Cancer Research, ISSN 0008-5472, 07/2017, Volume 77, Issue 13 Supplement, pp. 4450 - 4450
Journal Article
Nature Genetics, ISSN 1061-4036, 2012, Volume 44, Issue 12, pp. 1330 - 1335
Journal Article